Retatrutide 40mg
The world's first triple receptor agonist (GLP-1, GIP & Glucagon) in a pre-filled 40mg pen. EU manufactured, third-party tested.
Triple Mechanism of Action
Retatrutide activates three receptors simultaneously — a breakthrough in metabolic research.
GLP-1 Receptor
Reduces appetite, improves blood sugar control, and promotes satiety.
GIP Receptor
Enhances insulin sensitivity and supports fat metabolism.
Glucagon Receptor
Increases energy expenditure and promotes direct fat breakdown.
Clinical Data
Body weight in 48 weeks
Waist circumference
Response rate
Mechanism of action
Retatrutide Compared
| Feature | Retatrutide | Semaglutide | Tirzepatide |
|---|---|---|---|
| Receptors | GLP-1 + GIP + Glucagon | GLP-1 | GLP-1 + GIP |
| Weight Loss | −24% | −15% | −21% |
| Mechanism | Triple | Single | Dual |
| Generation | 3rd Generation | 1st Generation | 2nd Generation |
Retatrutide
- Receptors
- GLP-1 + GIP + Glucagon
- Weight Loss
- −24%
- Mechanism
- Triple
- Generation
- 3rd Generation
Semaglutide
- Receptors
- GLP-1
- Weight Loss
- −15%
- Mechanism
- Single
- Generation
- 1st Generation
Tirzepatide
- Receptors
- GLP-1 + GIP
- Weight Loss
- −21%
- Mechanism
- Dual
- Generation
- 2nd Generation
Product Details & Dosage
Technical Specifications
- Active Substance
- Retatrutide
- Dosage
- 40mg / Pen
- Form
- Pre-filled Pen
- Purity
- ≥98% (HPLC)
- Origin
- EU Manufactured (GMP)
- Storage
- 2–8°C
Recommended Titration
Starting dose for tolerability assessment
Gradual increase
Build-up phase
Maintenance dose (individualized)
Always consult a qualified physician before use. Individual dosage may vary.
Quality Assurance
Every batch is comprehensively tested. All certificates of analysis are publicly available.
Purity analysis ≥98%
Pyrogen-free verified
Molecular identity confirmed
Bioburden tested
Frequently Asked Questions About Retatrutide
Retatrutide 40mg
Pre-filled Pen · EU Manufactured · COA Included · 1–3 Day Delivery